Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including...
Vivoryon N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Both VIVIAD and VIVA-MIND...
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer™s Disease to Proceed...
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimers Disease Small molecule varoglutamstat,...